QIAGEN

QIAGEN NV is a provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The firm automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D, and industrial applications, primarily forensics). The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

QIAGEN surpasses 2022 targets, eyes growth in diagnostics and biopharma

QIAGEN's strong performance in 2022 exceeded expectations, supported by robust financials and strategic acquisitions.
Despite market challenges, the company remains confident in achieving its 2023 targets, focusing on growth opportunities in diagnostics and biopharma.
Emphasis on innovation, customer knowledge, and strategic shifts position QIAGEN well for sustained growth and leadership in the industry.

QIAGEN surpasses Q1 sales targets, eyes China growth opportunities

QIAGEN's Q1 2023 performance exceeded expectations, with strong sales growth and margin improvements.
The company remains focused on driving growth through product innovation and strategic market expansion.
Challenges include cautious customer spending and evolving market dynamics, particularly in China.
Opportunities lie in capitalizing on strong product performance, investing in new solutions, and expanding market reach.

QIAGEN reports strong Q2 earnings, eyes China growth opportunities

QIAGEN's Q2 performance was solid, driven by key growth areas, but challenges persist with net sales decline and market volatility. The company's strengths in base business sales and focus on growth pillars position it well for future opportunities in China and market expansion.

QIAGEN surpasses Q3 expectations, focuses on sustained growth strategies

QIAGEN's Q3 2023 performance exceeded expectations, showcasing strong financials and strategic leadership changes, with a reaffirmed full-year outlook for 2023.
The company's strengths lie in successful product pillars, sustained growth strategies, and a strategic focus on non-COVID products in key markets.
Challenges include debt repayment impacts, external market uncertainties, and competitive differentiation in expanding product offerings, while opportunities exist in market expansion, innovation, and automation investments.

QIAGEN surpasses Q4 expectations, eyes strategic growth opportunities

QIAGEN's Q4 performance exceeded expectations, showcasing strong growth and profitability.
Challenges include potential risks in Q1 and delays impacting certain product growth.
Strategic investments and upcoming launches present opportunities for continued growth and market expansion.
Overall, QIAGEN's focus on innovation and strategic acquisitions positions them for sustained success in the future.

QIAGEN beats Q1 sales targets, eyes FDA approvals for growth

QIAGEN's Q1 2024 performance exceeded expectations, with strong sales in Diagnostic Solutions. The company reaffirmed its full-year outlook and highlighted advancements in its product portfolio. Despite challenges in the Chinese market, QIAGEN remains focused on growth opportunities and efficient capital allocation.

QIAGEN surpasses Q3 expectations, boosts outlook amid leadership change

QIAGEN delivered strong Q3 results, surpassing expectations and demonstrating improved profitability. Despite leadership changes, the company's strategic initiatives and global positioning bode well for future growth and resilience in the face of market dynamics.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today marked World TB Day by announcing its QuantiFERON blood test has been used to screen patients for tuberculosis (TB) infection more than 100 million times since its launch – an achievement that cements its status as the gold standard in the fight against this contagious and often deadly disease. Used to test patients in over 130 countries, the fourth generation QuantiFERON®-TB Gold P

QIAGEN Reaches Milestone With 100 Million QuantiFERON Tests Used to Detect TB

GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2021, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN's website here. QIAGEN will provide printed copies of the 2021 Annual Report to shareholders free of charge upon request. To obtain a printed

QIAGEN Announces 20-F Annual Report Filing for 2021 Results

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?

Why Is Qiagen (QGEN) Down 11.3% Since Last Earnings Report?

SAN DIEGO--(BUSINESS WIRE)--Element Biosciences Partners with QIAGEN to Validate a Selection of QIAseq Targeted Library Construction Chemistries on Element's AVITI System

Element Biosciences Partners with QIAGEN to Validate a Selection of QIAseq Targeted Library Construction Chemistries on Element's AVITI™ System

Is QIAGEN (QGEN) a great pick from the value investor's perspective right now? Read on to know more.

Is QIAGEN (QGEN) a Great Stock for Value Investors?

QIAGEN N.V. (QGEN) CEO Thierry Bernard on Q4 2021 Results - Earnings Call Transcript

High demand for COVID-19 test products and improving trends in the non-COVID portfolio drove QIAGEN's (QGEN) fourth-quarter revenues.

QIAGEN (QGEN) Q4 Earnings Surpass Estimates, Margins Down

Qiagen N.V.  QGEN clocked Q4 revenues of $582.39 million, +2% Y/Y, and well above the consensus of $461.30 million.

Qiagen Q4 Earnings Beat Expectations On High Demand For COVID-19 Tests, Issues FY22 Guidance

VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the fourth quarter and full-year 2021. Net sales for Q4 2021 rose 2% (+4% CER) to $582 million from Q4 2020, well ahead of the outlook for a 9% CER decline. Sales were driven by high demand for COVID-19 test products and confirmed good trends in the non-COVID portfolio. Adjusted diluted earnings per share (EPS) were $0.74 ($0.75 CER) compared to the Q4 2021 outlook for at least

QIAGEN beats outlook for fourth quarter and full-year 2021, delivers 22% CER full-year sales growth from non-COVID products

HILDEN, Germany & GERMANTOWN, Md. & SHANGHAI--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its QuantiFERON tuberculosis (TB) testing solution has gained additional momentum with the approval of the fourth generation of this modern gold standard test in China and a new endorsement from the World Health Organization (WHO). Among the recent developments: China's National Medical Products Administration (NMPA) has approved QuantiFERON-TB Gold Plus (Q

QIAGEN's New Generation of QuantiFERON TB Test Gains Chinese Approval and Renewed WHO Recommendation

HILDEN, Germany, & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has completed a U.S. government contract to equip public health laboratories across the country with the QIAcuity digital PCR system to monitor the spread of the COVID-19 pandemic by testing wastewater for the presence of SARS-CoV-2 pathogens. QIAGEN has shipped more than 35 QIAcuity systems to state and local health laboratories as part of a multi-million-dollar contr

QIAGEN Completes U.S. Federal Contract to Equip Local Public Health Authorities with QIAcuity Digital PCR System for COVID-19 Surveillance

VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN N.V. to release results for Q4 2021 and Full-Year of 2021

QIAGEN N.V. to release results for Q4 2021 and Full-Year of 2021

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its new QIAwave product line by launching three nucleic acid extraction kits that use fewer components and produce less waste than existing ones. They are the first of their type to use both recycled plastics and space-saving chemical concentrates. The QIAwave RNA Mini Kit, QIAwave DNA Blood & Tissue Kit and QIAwave Plasmid Miniprep Kit use up to 63% less plastic and u

QIAGEN Launches QIAwave Portfolio of Environmentally Friendly Products

QIAGEN's (QGEN) artus SARS-CoV-2 Prep&Amp UM is faster than standard processes and can spot the virus more reliably, including the new Omicron variant.

QIAGEN (QGEN) to Boost Testing Capacity With Liquid-Based Kit

HILDEN, Germany & GERMANTOWN, Maryland--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced important enhancements in the commercialization of its QIAstat-Dx syndromic testing solution – which enables laboratories and hospitals worldwide to test patients for multiple pathogens from one sample – with new tests and the launch of a higher-throughput version that includes a new level of walk-away efficiency through the new QIAstat-Dx Smart Drawer. The test enhan

QIAGEN expands QIAstat-Dx syndromic testing menu and announces launch plans for new QIAstat-Dx Rise higher-throughput version

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to the growing number of applications for QIAcuity, its ultrasensitive digital PCR (dPCR) platform that has set new standards by using so-called nanoplates to process samples in two hours rather than the five hours required by other systems. QIAGEN has entered into two new collaborations that extend the QIAcuity ecosystem: A collaboration with Atila BioSystem

QIAGEN Strengthens Growing Portfolio of Applications for Its Digital PCR Platform QIAcuity With New Collaborations

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced important expansion initiatives for its QuantiFERON franchise, building on its status as the gold standard for detection of tuberculosis, while developing new applications for this technology designed to detect potentially deadly latent diseases. The new initiatives are expected to help drive further growth of the QuantiFERON franchise. A quantum leap from the traditional

QIAGEN Expands QuantiFERON Portfolio in the Fight Against TB

QuidelOrtho Corp

Thermo Fisher Scientific

Stocks like Thermo Fisher (TMO), QIAGEN (QGEN) and Quidel (QDEL) are expected to gain from increasing testing demand.

3 Diagnostics Stocks in Focus Amid the Omicron Outbreak

QIAGEN (QGEN) will develop a diagnostic assay that can identify the Denovo Genomic Marker 1 in patients with lymphoid cancer.

QIAGEN (QGEN), Denovo to Develop CDx Test for Lymphoid Cancer

SAN DIEGO and GERMANTOWN, Md. and HILDEN, Germany, Dec. 9, 2021 /PRNewswire/ -- Denovo Biopharma LLC and QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a collaboration to develop a blood-based companion diagnostic (CDx) test to identify patients expressing Denovo Genomic Marker 1 (DGM1™) who are likely to respond to Denovo's investigational cancer drug DB102™ for treatment of diffuse large B-cell lymphoma (DLBCL), one of the most common lymphoid cancers.

Denovo Biopharma and QIAGEN partner to develop companion diagnostic test for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL)

GERMANTOWN, Md. & HILDEN, Germany & SAN DIEGO--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Denovo Biopharma LLC today announced a collaboration to develop a blood-based companion diagnostic (CDx) test to identify patients expressing Denovo Genomic Marker 1 (DGM1TM) who are likely to respond to Denovo's investigational cancer drug DB102TM for treatment of diffuse large B-cell lymphoma (DLBCL), one of the most common lymphoid cancers. Under the agreement, QIAGEN will d

QIAGEN and Denovo Biopharma Partner to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)

QIAGEN's (QGEN) QuantiFERON SARS-CoV-2 assay enables a comprehensive assessment of immunity developed by COVID-19 vaccines.

QIAGEN (QGEN) Gets CE Mark for QuantiFERON SARS-CoV-2 Assay

Qiagen (QGEN) Down 1.9% Since Last Earnings Report: Can It Rebound?

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the CE marking of its QuantiFERON® SARS-CoV-2 assay that measures T-cell responses to SARS-CoV-2 and aids in the assessment of immunity in individuals who have received COVID-19 vaccination. COVID-19 vaccines stimulate the body to produce antibodies and activate T-cells to fight a SARS-CoV-2 infection. Serology tests, which measure the antibodies, often generate positive t

QIAGEN Launches CE-marked Version of QuantiFERON® SARS-CoV-2 to Assess T-cell Response to COVID-19

QIAGEN (QGEN) and DiaSorin gained FDA approval for their jointly-created LIAISON QuantiFERON-TB Gold Plus assay for use on DiaSorin's automated LIAISON XS platform.

News for QIAGEN Stock (QGEN)